Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects

This publication has 53 references indexed in Scilit:

• Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow
  Molecular Therapy, 2007
• Angiogenic Response Caused by Oncolytic Herpes Simplex Virus–Induced Reduced Thrombospondin Expression Can Be Prevented by Specific Viral Mutations or by Administering a Thrombospondin-Derived Peptide
  Cancer Research, 2007
• The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention
  Molecular Cancer, 2007
• Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors
  Clinical Cancer Research, 2006
• A Histone Deacetylase Inhibitor Enhances Recombinant Adeno-associated Virus-Mediated Gene Expression in Tumor Cells
  Molecular Therapy, 2006
• Cyclin D1: polymorphism, aberrant splicing and cancer risk
  Oncogene, 2006
• Novel Three-Pronged Strategy to Enhance Cancer Cell Killing in Glioblastoma Cell Lines: Histone Deacetylase Inhibitor, Chemotherapy, and Oncolytic Adenovirus dl520
  Human Gene Therapy, 2006
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
  Nature Reviews Cancer, 2006
• Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes
  Molecular Immunology, 2005
• Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-κB/p65 DNA Binding
  Molecular Cancer Research, 2005